top of page

CELL4CURE

PERSONALIZED TOLERANCE

CELL4CURE- Personalized Tolerance

Cell4Cure AB is a Swedish, privately held cell therapy company committed to the development of treatments by inducing  immune tolerance. The company’s proprietary technology platform is based on dendritic cells mediating antigen-specific tolerance, and are intended for the prevention or cure of diseases where the immune system is the enemy.

The company’s first clinical study, Toler8, is focusing on inducing tolerance to FVIII thereby preventing the occurrence of FVIII inhibitors in hemophilia A patients. 

 

Cell4Cure will as a first step deliver value to patients and shareholders by advancing this program to clinical proof of concept. 

INVEST IN A HEALTHIER FUTURE

Explore opportunities with Cell4Cure 

WORLD LEADING TECHNOLOGY PLATFORM

Cell4Cure´s patented technology platform makes use of the the body´s own way of introducing antigen specific tolerance. 
Insights

Press Releases & News

More PressReleases & News

Subscribe to our Press Releases

By filling out the form you are approving that Cell4Cure AB stores your information. Read more about our integrity policy (in Swedish) here.

Thankyou for subbmitting 

bottom of page